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http://www.biomedcentral.com/1746-6148/9/42RESEARCH ARTICLE Open AccessThe effect of robenacoxib on the concentration
of C-reactive protein in synovial fluid from dogs
with osteoarthritis
David Bennett1*, Peter David Eckersall2, Mary Waterston2, Veronica Marchetti3, Alessandra Rota3,
Eilidh McCulloch4 and Silvia Sbrana3Abstract
Background: Robenacoxib is a novel and highly selective inhibitor of COX-2 in dogs and cats and because of its
acidic nature is regarded as being tissue-selective. Thirty four dogs with stifle osteoarthritis secondary to failure of
the cranial cruciate ligament were recruited into this study. Lameness, radiographic features, synovial cytology and
C-reactive protein concentrations in serum and synovial fluid were assessed before and 28 days after commencing
a course of Robenacoxib at a dose of 1 mg/kg SID.
Results: There was a significant reduction in the lameness score (P < 0.01) and an increase in the radiographic score
(P < 0.05) between pre- and post-treatment assessments. There was no difference between pre- (median 1.49 mg/
l; Q1-Q3 0.56-4.24 mg/L) and post – (1.10 mg/L; 0.31-1.78 mg/L) treatment serum C-reactive protein levels although
synovial fluid levels were significantly reduced (pre- : 0.44 mg/L; 0.23-1.62 mg/L; post- : 0.17 mg/L; 0.05-0.49 mg/L)
(P < 0.05). There was no correlation between C-reactive protein concentrations in serum and matched synovial
fluid samples.
Conclusions: Robenacoxib proved effective in reducing lameness in dogs with failure of the cranial cruciate ligament
and osteoarthritis of the stifle joint. The drug also reduced levels of C-reactive protein in the synovial fluid taken from
the affected stifle joint. Robenacoxib appears to reduce articular inflammation as assessed by C-reactive protein which
supports the concept that Robenacoxib is a tissue-selective non-steroidal anti-inflammatory drug.
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Robenacoxib is a novel and highly selective inhibitor of
COX-2 in cats and dogs [1,2] and is now available in sev-
eral European countries for the treatment of articular pain
and inflammation. Robenacoxib is an acidic NSAID and is
highly bound to plasma proteins with the result that it
concentrates in inflamed tissues such as an arthritic joint
[3], thereby displaying the property of tissue selectivity [4].
The study described here was designed to show the effect
of robenacoxib on the concentrations of blood and syn-
ovial fluid C-reactive protein (CRP), a recognized marker
of inflammation. Robenacoxib was selected for this study* Correspondence: David.Bennett@glasgow.ac.uk
1School of Veterinary Medicine, College of Medical, Veterinary and Life
Sciences, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH,
Scotland
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reproduction in any medium, provided the orbecause it has this capacity for tissue selectivity. In
addition to assessing the effect of robenacoxib on CRP
concentrations in blood and synovial fluid, its effect on
lameness, radiographic changes and synovial fluid cytology
in clinical cases of OA was investigated.
CRP is one of several acute-phase proteins (APPs) that
can be used to assess the innate immune system’s systemic
response to infection, inflammation or trauma [5-7].
These proteins are traditionally measured in serum and by
definition their concentration increases by more than 25%
in response to pro-inflammatory cytokines such as IL-6,
IL-1 and TNFα which are released during the disease
process. APPs are highly sensitive indicators of inflamma-
tion but unfortunately lack specificity. APPs are largely
produced by the liver, although there is increasing evi-
dence that other tissues can be a source [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been widely studied in human rheumatology as bio-
markers of arthritic disease [9-13] and can be used to
monitor response to therapy including NSAIDs [14].
Serum levels of SAA and CRP have been shown to correl-
ate with disease activity in different types of inflammatory
arthritis [15]. Buch et al. (2005) [16] examined the value of
CRP as a predictor of response to therapy in patients with
rheumatoid arthritis. The authors found that reduction in
CRP levels following therapy was predictive of a clinical
response within twelve to twenty-four weeks in over 50%
of patients. Measurement of CRP is also a useful test in
the diagnosis of infection after total knee arthroplasty [17]
and septic arthritis in children [18]. Many studies have
also examined concentrations of APPs in synovial fluid as
well as serum of patients with inflammatory joint disease.
In most cases serum levels are found to be higher than
synovial fluid levels [13,19,20] although Kumon and co-
workers [21] found that in some rheumatoid arthritis pa-
tients the synovial fluid levels of SAA exceeded the serum
concentrations.
Increased concentrations of APPs in plasma and syn-
ovial fluid of osteoarthritic patients has also been dem-
onstrated in man, although at lower levels compared to
the inflammatory arthropathies [13]. More sensitive as-
says such as the ELISA are recommended for detecting
the lower levels of APPs that are found in osteoarthritis
[12,22]. Such assays have demonstrated modestly ele-
vated blood levels of CRP in human osteoarthritic pa-
tients compared to aged-matched controls [23-26] and
that increased levels of CRP are associated with disease
progression [24,27,28] as well as with clinical severity
[22]. It has also been reported that elevations in CRP
may reflect events that may precede but ultimately lead
to radiographic progression in osteoarthritis [25,28]. In
addition elevated CRP has been found to be associated
with the severity of pain in human OA [26] and a rela-
tionship between elevated blood levels of CRP, elevated
synovial fluid levels of IL-6 and the presence of chronic
synovial inflammation as assessed histologically has been
described [22]. Pelletier et al. (2010) [29] reported that
higher baseline levels of serum CRP in human patients are
predictive of a greater risk of cartilage loss in OA and cor-
related with a worsening of symptoms including pain and
function. CRP was also found to be a good predictor of
the symptomatic response to treatment using NSAIDs.
However, Kerkhof and colleagues (2010) [30] reported that
although human knee OA was associated with 14% higher
serum CRP levels, this association disappeared after ad-
justment for age and body mass index.
Very few studies examining the usefulness of APPs as
biomarkers of canine arthritic disease have been published
[31,32]. Although there are differences within species as to
which APPs are most relevant to measure, CRP is acceptedas the most useful in the dog, a situation similar to man.
Caspi et al. [31] reported that serum CRP was found to
be more elevated in dogs with active immune-based
polyarthritis than in dogs with inactive disease or in af-
fected dogs treated with corticosteroids, suggesting it might
be a useful marker for the inflammatory arthropathies.
Hurter and co-workers [33] examined the possible role of
serum CRP as a marker of disease in OA by measuring
serum levels in 29 clinically affected dogs. In this study all
the measured values were within the normal limits, al-
though they had a tendency to be higher than the control
group. The authors concluded that serum CRP was not a
useful clinical marker for canine OA. There have been no
studies published on the measurement of CRP in the syn-
ovial fluid of dogs although one study did measure SAA
levels in both serum and synovial fluid of dogs with inflam-
matory and non-inflammatory joint disease [34]. The num-
bers of dogs were too low to make any valid conclusions.
A recent collaborative study between the Universities of
Glasgow and Pisa suggested that synovial fluid levels of
CRP may be a useful marker of OA in the dog [35] and
provided the stimulus for the present study. We studied
34 dogs with hindleg lameness caused by failure of the
cranial cruciate ligament and secondary osteoarthritis.
Blood and synovial fluid samples were collected when the
dogs were presented and repeat samples were taken one
month later after a course of Robenacoxib and CRP con-
centrations in the samples determined. The hypothesis
was that treatment with the NSAID would significantly re-
duce the levels of synovial fluid CRP thus demonstrating
its usefulness as a biomarker of articular inflammation.
Results
Most of the dogs were of the heavier breeds and cross-
breeds with a mean body weight of 35.3 Kg and a range
of between 19–60 Kg (Table 1). The most common
pure-breeds were the Labrador Retriever (23.5%) and the
Golden Retriever (11.8%) although cross-breeds accoun-
ted for 26.5% of the total. The mean age was 4.7 years
with a range of 1–12 years. The mean duration of lame-
ness was 11.1 weeks with a range between 1.4-34 weeks.
The mean body condition score was 3.0 (ideal) with a
range of between 2 (lean) and 5 (obese). No adverse ef-
fects relating to the NSAID were reported. Twenty-three
of thirty-one dogs improved their lameness score after
the course of Robenacoxib; by one grade in 16 dogs and
by two grades in 7 dogs. The score stayed the same in 8
dogs (Figure 1). There was a significant reduction in
lameness score between pre- (median = 3.0; Q1-Q3 =
3.0-4.0) and post- (2.0; 2.0-2.25) treatment assessments
(P < 0.01). The radiographic score was unchanged in 20
of 31 dogs and was increased by one grade in 7 dogs
and by two grades in 4 dogs (Figure 2). There was a sig-
nificant difference between pre- (5.0; 2.0-6.0) and post-
Table 1 Summarising details of the 34 dogs with stifle
osteoarthritis
Case Sex Breed Age Weight CCL L. D. P.T. BCS
1 M Labrador R 48 36 L 45 0 3
2 M Labrador R 50 36 R 20 0 3
3 F Golden R 60 32 R 90 0 3
4 M New Foundland 30 50 R 120 0 2
5 M Golden R 60 30 R 60 0 3
6 F Cross breed 48 26 L 20 0 2
7 F Spinone 36 31 L 45 0 3
8 M Bullmastiff 60 56 R 30 0 4
9 F Cross breed 120 28 L 20 0 3
10 M Pittbull 84 36 L 120 0 3
11 M Pittbull 84 36 R 60 0 3
12 M Labrador R 40 28 R 20 0 3
13 M Labrador R 36 27 L 48 0 3
14 F Beagle 96 20 R 72 0 4
15 F Shar pei 48 28 R 30 0 3
16 F Corso 12 54 L 120 0 2
17 M Golden R 60 42 L 90 0 5
18 F Cross breed 48 34 L 180 0 3
19 M Cross breed 48 34 R 20 0 3
20 M German Shepherd 72 24 L 30 0 4
21 F Cross breed 60 32 R 90 0 4
22 M Labrador R 24 36 R 180 0 3
23 F Labrador R 36 43 L 10 0 3
24 F Pittbull 96 40 R 30 0 4
25 M Cross breed 84 38 L 240 0 3
26 F Australian Shepherd 120 24 L 120 0 2
27 M Corso 24 48 L 180 0 3
28 M Great dane 30 60 R 90 0 3
29 M Cross breed 48 35 L 180 0 4
30 F Golden R 36 29 R 15 0 3
31 F Labrador R 60 42 R 150 0 4
32 F Cross breed 60 25 R 60 0 3
33 M Cross breed 72 41 L 30 0 4
34 M Labrador R 36 20 R 30 0 4
M: male; F: female; CCL: cranial cruciate ligament; L: left; R: right; L.D.: lameness
duration; P.T.: previous treatment; BCS: body condition scoring. Age is given in
months, weight in Kg.
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The synovial fluid score was the same in 16 of 31 dogs,
had decreased by one grade in 9 cases and by two grades
in 2 cases. The score had increased by one grade in 4
cases (Figure 3). There was not a statistically significant
difference between pre- (2.0, 1.7-3.0) and post- (2.0, 1.0-
2.0) treatment synovial fluid scores although a tendency
for a decrease was observed (p < 0.1).Serum CRP concentration
The ELISA to determine the concentration of CRP in
serum has been previously validated by Kjelgaard-Hansen
and colleagues (2003) [36] and was confirmed in our study
(detailed data not provided) (Figure 4). Fifteen of 24 dogs
had a decreased concentration of CRP and 9 cases an in-
crease after treatment (Figure 5). There was no significant
difference between pre- (median 1.49 mg/l; Q1-Q3 0.56-
4.24 mg/L) and post- (1.10 mg/l; 0.31-1.78 mg/L) treat-
ment concentrations of serum CRP.
Synovial fluid CRP concentration
Validation of the ELISA to measure CRP in synovial fluid
showed an intra-assay co-efficient of variance (CV) of 8.9
+/− 7.9% (mean ± SD) for duplicate samples (n = 34). The
precision profile based on the CVs of the duplicates
(Figure 4) showed that higher CVs were given with low
concentrations of CRP in synovial fluid. Inter-assay CVs
were 19.4% at a mean concentration of 6.2 mg/L and
17.5% at a mean concentration of 49.1 mg/L (n = 5). The
accuracy of the assay in synovial fluid, determined by cal-
culating the recovery of CRP spiked into a pool of the fluid
showed a recovery of 113% (Figure 6) and a correlation
of R2 = 0.993 for expected against observed concentra-
tions. The assay had a limit of detection of 0.05 mg/L,
based on the concentration detectable at 3 standard devia-
tions from the mean of the blank samples over 7 assays
and allowing for the dilution of synovial fluid (1:200) used
in the assay. The Western blot (Figure 7) confirmed the
presence of CRP in synovial fluid with the double band
known to be present in this species evident in both syn-
ovial fluid and serum samples.
Nineteen of 26 cases had a lower concentration of
CRP in the post-treatment sample (Figure 8). Seven
cases had an increase. The post- treatment CRP concen-
tration in synovial fluid (0.17 mg/L; 0.05-0.49 mg/L) was
significantly lower compared to the pre-treatment level
(0.44 mg/L; 0.23-1.62 mg/L) (p < 0.05).
The concentrations of CRP in both the pre- and post-
treatment synovial fluid samples were significantly greater
than the levels (median 0.14 mg/L SD+/− 0.32 mg/L) mea-
sured in normal synovial fluid samples (p < 0.05).
There was no correlation between levels of CRP in
matched serum and synovial fluid samples, neither in
the pre-treatment nor post-treatment samples.
Discussion
A 28-day course of Robenacoxib proved effective in re-
ducing the lameness scores of dogs with stifle osteoarth-
ritis secondary to failure of the cranial cruciate ligament.
The reduction in lameness scores was statistically signifi-
cant. It is accepted that a deficiency of the study was the
use of a subjective assessment of lameness although all
the lameness assessments were carried out by the same
Lameness Score
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5
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33
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Figure 1 Graph showing pre- and post-treatment values for lameness score.
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re-evaluating the animal a month later. More objective
measurements of lameness such as force plates and pres-
sure mats were not available for this study. The use of
activity monitors was not feasible since part of the case
management involved restricted exercise during the
course of the NSAID. The analgesic properties of
NSAIDs for joint pain are well known and clinical im-
provement has been reported with many different com-
pounds [37] Robenacoxib preferentially inhibits the
COX-2 enzyme which is involved in the pathophysiology
of joint pain and central sensitization [2]. It is possible
that some of the clinical improvement was due to the re-
stricted exercise regime used, although all of the dogs
had already been placed on a controlled exercise plan by
the referring veterinarian.
Although in 58% of cases the radiographic scores did
not change, overall there was a statistically significant in-
crease in the radiographic score over the period of the
study indicating that the radiographic changes had
progressed. This is to be expected since once initiated,
OA is a gradually progressive disease and there is little
evidence that NSAIDs can influence the structural
pathological changes that occur within the joint. The
radiographic score that was used in this study is very
much biased towards assessing osteophyte formation andRx Sco
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Figure 2 Graph showing pre- and post-treatment values for the radiochanges in bone opacity and the only study which has
shown an effect of a NSAID on such bony changes is an
experimental study in the dog [38,39]. These studies in-
volved only small numbers of dog and the protocol meant
that the NSAID was given from day one when the arthritis
was initiated (by sectioning the cranial cruciate ligament),
a situation very different from the clinical one, where the
disease is generally well advanced before clinical signs are
evident and treatment required.
The synovial fluid score based on total nucleated cell
counts was not significantly affected by the course of
Robenacoxib. Although it is generally accepted that the
total nucleated cell count (neutrophils, lymphocytes and
macrophages) does reflect the level of inflammation
within the joint [40], there have been no studies validat-
ing the use of nucleated cell counts as an outcome
measure in the treatment of osteoarthritis.
A major finding in this study was the statistically signifi-
cant decrease in the concentration of CRP in synovial fluid
following the month’s course of Robenacoxib. There was
no statistically significant difference in the concentration of
serum CRP between the pre- and post-treatment samples.
This supports the view of Hurter et al. [33] who concluded
that serum CRP was not a useful marker of OA in the dog.
Our study is the first to have reported CRP concentrations
in the synovial fluid of dogs and the results support there
21 23 25 27 29 31 33
Pre
Post
graphic score.
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Figure 3 Graph showing pre- and post-treatment values for the synovial fluid score.
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joint inflammation and a useful monitor of response to
anti-inflammatory treatment. The concentrations of CRP
detected in the synovial fluid were much lower than the
blood levels. Although the concentrations of synovial fluid
CRP in the OA dogs were statistically significantly higher
than found in normal synovial fluid, in approximately a
third of cases the levels fell within the normal range even
though they still decreased after therapy. The measure-
ment of these relatively low levels of CRP does require a
very sensitive assay such as the ELISA used in this study.
Immunoturbidimetric assays, used in previous reports
[41,42] had a limit of detection of 1 mg/L and are thus not
sensitive enough to provide meaningful results, whereas
the ELISA used in our study had a lower limit of detection
of 0.05 mg/L. The assay was validated for use in measuringFigure 4 Precision profiles of CRP in (A) serum (n = 39) and (B)
synovial fluid (n = 34) assayed in duplicate by ELISA.this protein in synovial fluid and demonstrated equivalent
precision to that for serum CRP while the accuracy of the
assay was also acceptable with a recovery rate of 113%
from spiked samples. Whilst the antibody used in the
Western blot was not the same as used in the ELISA,
the immune blot does confirm that CRP is present in
canine synovial fluid.
It is possible that drugs used in inducing and
maintaining general anaesthesia can cause alterations in
the blood (and therefore perhaps also in synovial fluid)
concentration of CRP in both humans [43-45] and dogs
[46] although in all these studies the patients also under-
went surgery and this is much more likely to be the
stimulus for elevation of CRP levels. In our study, both
pre- and post-treatment blood samples were collected
from conscious dogs but the 2 synovial fluid samples
were collected whilst the dogs were anaesthetized, within
minutes of the dog losing consciousness and before any
surgical stimulus. The fact that both synovial fluid sam-
ples were collected under general anaesthesia means that
comparison of CRP concentrations in the pre-and post-
treatment samples should not be compromised, even if
the anaesthetic agents do have an effect since the same
anaesthetic protocol was always used and any effect of
the anaesthetic is likely to take several hours [46].
The origin of synovial CRP is not known. It could ori-
ginate from the blood or be locally produced by the syn-
ovial membrane. There was no correlation between the
concentrations of CRP in synovial fluid and matched
serum sample suggesting that levels in the synovial fluid
were not merely a reflection of the serum levels. How-
ever, it is possible that CRP in synovial fluid is solely a
result of transfer from blood but that there is sufficient
variation in the rate of transfer between dogs leading to
the lack of correlation. Alternatively, blood derived CRP
may be diluted to varying degrees by the synovial fluid.
Arthritic joints tend to have much greater volumes of
synovial fluid than normal joints, which can vary be-
tween cases, although even in normal joints synovial
fluid concentrations of CRP tend to be lower than
matched blood levels. Local production of CRP within
Serum CRP
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Figure 5 Graph showing pre- and post-treatment values for CRP concentration in serum.
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blood and synovial levels although to date, there have
been no studies published to show local production of
CRP within the joint although this has been shown with
SAA in man [19,21], dog [34] and horse [47]. There have
been several studies which have shown the local produc-
tion of CRP in other inflamed tissues proving that the
liver is not the only source although it is probably the
major producer, particularly when the patient is suffering
from a systemic illness. A study by Maekawa et al. [48]
demonstrated a significantly elevated gene expression of
CRP in human patients with gingivitis and periodontitis.
The CRP gene was up-regulated in fibroblasts and endo-
thelial cells rather than the epithelial cells of the oral
mucosae. Another study demonstrated CRP gene expres-
sion in adipose tissue from human patients [49]. Adipose
tissue is commonly found within the joint capsule and,
in addition, the stifle joint contains the infra-patellar fat
pad and this coupled with the fact that fibroblasts are
the commonest cell found within the joint capsule
means that it is highly likely that CRP is produced lo-
cally within the joint. Further studies, particularly deter-
mining CRP gene expression within the synovium and
looking for synovial isotypes of CRP are required.Figure 6 Accuracy of the CRP ELISA for determination of CRP in
synovial fluid: recovery of spiked CRP from pooled synovial fluid.Robenacoxib has been shown to persist within inflamed
tissues for much longer than it remains in the circulation
[3]. This has lead to the concept of tissue selectivity [4] by
which a drug concentrates in the inflamed tissues where it
is required and has a prolonged anti-inflammatory effect.
The fact that the half-life of the drug is reduced in the cir-
culation means it is less likely to cause adverse effects on
tissues such as the liver and kidney thus contributing to37
20
15
Figure 7 Western blot of canine synovial fluid (Tracks 1& 2),
canine serum (tracks 3 & 4) purified canine CRP (track 5) and
molecular weight markers (Mw).
SF CRP
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Figure 8 Graph showing pre- and post-treatment values for CRP concentration in SF.
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pears to reduce synovial levels of CRP supports a local ef-
fect and the concept of tissue selectivity.
CRP production is mediated by the catabolic cyto-
kines, particularly IL-6, TNFα and IL-1. It is known that
PGE2 regulates the production of cytokines such is IL-6,
IL-8, IL-11, macrophage colony stimulating factor and
vascular endothelial growth factor [50-52], possibly in-
volving the activation of the PGE2 receptors, EP2 and
EP4 with an increase in cyclic AMP. By inhibiting PGE2
activity and thus cytokine production, NSAIDs will
affect the acute phase response and also have other be-
neficial effects eg IL-6 is known to stimulate PGE2
production and matrix metalloproteinase production
within the joint leading to articular cartilage damage,
macrophage colony stimulating factor activates mono-
cytes/macrophages to produce more catabolic cytokines
and vascular endothelial growth factor plays an import-
ant role in angiogenesis and endothelial migration dur-
ing the development of synovitis [53-56]. These effects
would be additional benefits of using Robenacoxib (and
other NSAIDs) in the treatment of osteoarthritis and
help to explain why NSAIDs at the level of the joint may
result in the slowing of disease progression [38,39]. We
found no correlation between CRP concentrations (in
blood or synovial fluid) and lameness or radiographical
(pre-treatment) scores.
It is worth noting that in dogs 8, 9 and 30 where the
NSAID was stopped prematurely, there was a marked
increase in the concentration of synovial fluid CRP in
the post-treatment sample (18, 33 and 49 fold increases
respectively). This was significantly greater than for any
other case where there had been an increase after treat-
ment; in all these other cases, the animal was still re-
ceiving the NSAID when the post-treatment sample
was taken. This observation raises the question as to
whether the NSAID should be gradually withdrawn
after a therapeutic course rather than finished abrupt-
ly although further studies are necessary to investi-
gate this.Conclusions
Robenacoxib proved to be safe and effective in reducing
lameness scores (p < 0.01) in dogs with failure of the cra-
nial cruciate ligament and stifle OA. The drug did not sig-
nificantly alter serum concentrations of CRP but did
significantly reduce synovial fluid concentrations (p < 0.05),
suggesting a local anti-inflammatory effect consistent with
its property of being tissue selective. There was no correl-
ation between matched serum and synovial fluid concen-
trations of CRP, raising the possibility of a local production
of CRP within the joint, a possibility worthy of further in-
vestigation. CRP concentration within synovial fluid is a
potential biomarker of articular inflammation and may
prove useful in monitoring ant-inflammatory responses to
therapeutic agents. Synovial fluid concentrations are much
lower than those found in serum and their accurate meas-
urement requires more sensitive assays (ELISA) than rou-
tinely used for serum.
Methods
Study protocol
A total of 34 dogs with OA secondary to failure of the
cranial cruciate ligament were included in the study. All
the dogs had to be free of other diseases and were not to
have received any medication for the 15 days prior to
presentation. The study was carried out in the Depart-
ment of Veterinary Clinics at the University of Pisa and
ethical permission for the study was granted by the com-
mittee for animal experimentation of the University of
Pisa. The age, sex, breed, body weight, affected joint and
duration of lameness were recorded for each dog. A full
physical examination, including a detailed orthopaedic
examination was carried out and a blood sample col-
lected when the dog first presented. Each dog was anes-
thetized and a radiographic examination performed on
both stifle joints and synovial fluid (from the affected
joint) was collected. Because of the surgical waiting list
at the clinic, it was normal practice to delay surgery for
2–3 weeks. In this study surgery was delayed for 4 weeks
over which time each animal was given a course of
Table 3 Details of the radiographic scoring scheme
a) For each of 11 different sites, the size of osteophytes was measured in millimetres
and a score was assigned:
0 Absence of osteophytes
1 Osteophytes
smaller than 2 mm
2 Osteophytes
between 2 and 5 mm
3 Osteophytes
greater than 5 mm
b)The osteophyte score for each site was totaled and then converted to a final
score of 1-3
From 0 to 10 Mild 1
> 10 to 20 Moderate 2
> 20 Severe 3
c) The final osteophyte score, bone opacity score, joint effusion score and global score
were summed to give the overall score (maximum possible 12)
Parameter Absent Mild Moderate Severe
Osteophytes 0 1 2 3
↑ Bone opacity 0 1 2 3
Joint effusion 0 1 2 3
Global score 0 1 2 3
Total maximum
score 12
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dose rate of 1 mg/kg SID orally without food. All ani-
mals where then re-assessed at the end of the 4 week
course, whilst still receiving the NSAID. Each animal
had a second physical examination with a detailed ortho-
paedic examination and a second blood sample was col-
lected, A further radiographic study was carried out and
a second synovial fluid sample was collected whilst the
dog was anaesthetized. Surgical treatment of the cruciate
rupture was carried out at this time, after the samples
had been collected. All the assessments were carried out
by the same observer and the initial scores were not
known to the observer when doing the re-assessments.
Whilst the dogs were receiving the NSAID, the owners
were instructed to restrict their animal’s exercise to ten mi-
nutes walk on a lead, 3 times a day. This was similar to that
which had already been instigated by the referring veterin-
arian. The owners were also asked to contact the clinic dir-
ect if any health problems arose during the study period.
Lameness scoring
The dogs were examined standing and at the walk and
the trot. A scoring system was used based on the sever-
ity of lameness using a modification of the method de-
scribed by Peterson and Keefe [57] (Table 2).
Body condition scoring
Body condition scoring was assessed using the method
described by Laflamme [58] ranging from 1 (emaciated)
to 5 (obese).
Radiographic scoring
A modification of previously described methods [35,59-61]
was used. The presence and size of osteophytes, at 11 dif-
ferent anatomical sites were assessed on both a medio-
lateral and craniocaudal radiograph of the affected stifle
joint; the sites were the lateral and medial trochlear ridges
of the femur, lateral and medial condyles of the femur,
proximal and distal poles of the patella, the fabellae, lateral/
medial/caudal edges of the tibia and the intercondylar area
of the femur. Based on the size of the osteophytes inTable 2 Details of the lameness scoring scheme (Modified
from Peterson and Keefe, [57])
Score Description
0 No detectable lameness at a walk or trot, no
detectable lateral weight shift whilst standing
1 No detectable lameness at a walk or trot and
minor lateral weight shift whilst standing
2 Lameness at a trot
3 Lameness at a walk and trot
4 Non-weight bearing at a trot
5 Non-weight bearing at walk and standingmillimetres, a score was given for each site (Table 3a).
These scores were totaled and converted into a final score
of 1–3 (Table 3b).
Joint effusion and an increase in radio-opacity of the
distal femur (along the trochlear margin on the medio-
lateral view) were also evaluated and scored as 0 (ab-
sent), 1 (mild), 2 (moderate) or 3 (severe). A global
score, intended to represent a subjective impression of
the overall disease severity, was also used, (0 normal
joint, 1 mild changes, 2 moderate changes and 3 severe
changes). The sum of all the recorded scores gave the
total radiographic score for each joint, the maximum
possible score being 12 (Table 3c).
Synovial fluid scoring
Synovial fluid was examined macroscopically and micro-
scopically and the scoring system used (from 0–3) was
based on the automated nucleated cell count (Table 4).
The total nucleated cell count gives an indication of the
synovial inflammation [40] but has not been validated as aTable 4 Details of the synovial fluid scoring scheme
(based on nucleated cell count)
Category Cell count Score
X106/ml
Not increased < 0.7 0
Slightly increased 0.7-1.5 1
Moderately increased < 1.5-3.0 2
Severely increased > 3.0 3
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fluid samples had to be less than 0.01 × 1012 cells per litre
which is consistent with minimal blood contamination.
This was important to ensure that significant amounts of
serum CRP had not leaked into the joint and that nucle-
ated cell counts accurately reflected synovial fluid numbers
rather than blood contamination..
The total nucleated cell count was done on 0.5 ml of
sample using the Hemat 8 (SEAC) analyzer. The diffe-
rential cell count (neutrophils, lymphocytes and macro-
phages) was performed on a smear of synovial fluid after
Romanowsky staining (Diff-Quik, Vetefarma). Before ana-
lysis the sample was treated with hyaluronidase (from bo-
vine testes-Sigma, Aldrich) to reduce the viscosity (2 drops
of a solution containing 150 U/ml of enzyme in PBS buffer
for 0.25 ml of sample) [62].Measurement of C-reactive protein concentration
Synovial fluid was centrifuged immediately after collec-
tion in plain tubes at 1500 g for 3 minutes and the
supernatant collected. All the serum and synovial fluid
samples were stored at −80°C until the CRP concentra-
tions were measured. CRP was measured using an
ELISA [63] available commercially (Tridelta Develop-
ment Limited, Ireland) and previously validated to
measure CRP in canine serum [36] with further valid-
ation in this study (intra-and inter-assay coefficients of
variance). The test was further validated for use with
synovial fluid by assessment of precision and accuracy
using this fluid as the sample matrix. Precision was de-
termined by calculation of inter assay CV with three
samples of synovial fluid assayed for CRP in 5 separate
assays. Intra assay CV was calculated as the mean of
the CV of duplicate samples of synovial fluid and also
plotted as a precision profile. To determine accuracy of
measurement of CRP in synovial fluid, purified canine
CRP (Life Diagnostics, NJ, USA) was dispensed at
25 mg/L, 12.5 mg/L and 6.3 mg/L in a pool of synovial
fluid with a low concentration of CRP. Following assay
for CRP, the mean recovery of the CRP was calculated
as a measure of the accuracy of the test.
The presence of CRP in synovial fluid was confirmed
by antibody cross reactivity on a Western blot following
sodium dodecyl sulphate polyacrylamide gel electrophor-
esis (SDS-PAGE) using established methods. The first
antibody was a sheep antibody raised against purified ca-
nine CRP at a dilution of 1:200 and the second antibody
was a rabbit anti- sheep IgG labelled with HRP (Abcam,
Cambridge, UK) with the blot developed using an Opti-
4CN kit (Biorad, Hemel Hempstead, UK). Samples were
2 synovial fluids and 2 sera with elevated concentrations
of CRP as determined by ELISA and a purified CRP
sample (Life Diagnostics, NJ, USA).Statistical analyses
Data obtained before and after treatment for the exam-
ined parameters (lameness score, radiographic score,
synovial fluid score, CRP concentration in serum and
synovial fluid) were compared by the Wilcoxon matched
pair signed rank sum test for non-parametric values. Syn-
ovial fluid CRP concentrations before and after treatment
were compared with normal values measured in a previ-
ous study, using the same assay (median = 0.14 mg/L +/−
0.32 mg/L), by the Wilcoxon matched pair signed rank
sum test for non-parametric values. Correlation between
the matched serum and synovial fluid CRP concentra-
tions was measured by calculation of the Pearson correl-
ation coefficient.
Eight cases were excluded from the statistical analyses
for synovial fluid CRP, ten cases for the serum CRP ana-
lyses and 8 cases for the lameness, radiographic and syn-
ovial cell count analyses. The reasons for this were:
 With cases 8, 9 and 30 the treatment protocol
was not completed since the administration of
Robenacoxib was stopped prematurely (in case 8
at 3 weeks, in case 9 at 1 week and in case 30 at
10 days).
 With case 29 the labeling of the pre- and post-
treatment samples was unclear.
 Case 28 had a very high concentration of CRP in the
post-treatment serum sample and a few days after
the second examination the dog showed signs of
systemic infection, notably pyrexia, leucocytosis,
vomiting and diarrhea which were not evident at the
time of the physical examination and it was highly
likely that the raised serum CRP was an early
response to this systemic infection.
 Cases 14, 32 and 33 were not returned for the
second examination after the owners declined
surgery.
 The post-treatment serum samples for cases 18 and
19 were lost in the clinic.
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